Jacobio Pharmaceuticals

Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company focusing on the development of innovative oncology and other therapies.

Business Model:

Revenue: $74.5M

Employees: 51-200

Rankings

Detailed Jacobio Pharmaceuticals Information

Geographic Data

Jacobio Pharmaceuticals headquarters map

Address: No. 88, Kechuang 6th Street, Beijing Economic Development Zone

City: Beijing

State: beijing municipality

Zip: 101111

Country: CN

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$102M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Jacobio Pharmaceuticals, founded in 2015 in Beijing China, is a clinical-stage biotech company dedicated to the development of global truly innovative drugs for the unmet needs in China and abroad. The vision and mission of Jacobio have become a global leader to provide revolutionary therapies for serious and life-threatening diseases such as cancer, autoimmune and infectious diseases. Jacobio is founded by seasoned executives from top global and local pharmaceuticals companies who have an astounding track record of success and backed by prestigious venture capital firms such as Lilly Asia Ventures and Qiming Capitals. Dr. Yinxiang Wang, the co-founder and chairman of Jacobio, also is one of the founders of Betta Pharmaceuticals, an A-share listed innovative pharmaceutical company, and the national "The Recruitment Program of Global Experts". The most senior management team has over 20 years of drug R&a;D experience and successfully brought several innovative drugs into the clinical and market stage. Within 3 years, Jacobio has quickly established a compelling drug R&a;D team of over 100 employees and one-stop capability covering target discovery, med-chemistry, pharmacology, CMC formulation, clinical, and registration. With those, the company has built up a rich pipeline of 8-10 assets with clear competitive advantages and excellent drug properties. JAB-3068, the most advanced program for Jacobio, has focused on a novel target potential for both immunotherapy and target therapy and enter Phase I clinical trial in US and IND approved at China and clinical trials would be initiate at China very soon.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
8/2021 HebeCell Series A 53M
8/2021 HebeCell Series A 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research